Stockscreener 앱 받기
10.70
0.09%
0.010
시간 외 거래:
10.70
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Forecast for TRVI Q1 Earnings? - MarketBeat
Trevi Therapeutics Q4 Earnings Call Highlights - MarketBeat
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Benzinga
Morgan Stanley Lowers Price Target for Trevi Therapeutics (TRVI) to $18.00 | TRVI Stock News - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley - MarketBeat
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating By Investing.com - Investing.com India
Trevi Therapeutics Chronic Cough Programs: FDA End-of-Phase 2 Meeting & Phase III PlansNews and Statistics - IndexBox
Trevi Therapeutics 2025 Annual Report Highlights: Haduvio Development, Clinical Progress, and Competitive Position - Minichart
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Trevi Therapeutics (TRVI) Earnings Transcript - AOL.com
TRVI: Today's Analyst Rating Maintained at Buy with $19 Target | - GuruFocus
Needham raises Trevi Therapeutics stock price target on trial plans By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00 - MarketBeat
Trevi Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Does Trevi Therapeutics (TRVI) have the potential to rally 102.07% as Wall Street analysts expect? - MSN
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - AlphaStreet
TRVI: Needham Raises Price Target to $24.00 and Maintains Buy Ra - GuruFocus
Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Decoding Trevi Therapeutics Inc (TRVI): A Strategic SWOT Insight - GuruFocus
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Analysis Recap: Is Trevi Therapeutics Inc subject to activist investor interestWeekly Market Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
TRVI: Positive clinical results and strong cash position set up pivotal chronic cough trials and market expansion - TradingView
TRVI: Positive clinical data and robust cash position set stage for pivotal chronic cough trials - TradingView
Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations - Investing.com
Trevi Therapeutics (TRVI) Advances Chronic Cough Trials with Str - GuruFocus
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates - Bitget
Trevi Therapeutics (NASDAQ:TRVI) Releases Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Trevi Therapeutics, Inc. (hereinafter referred to as "the Company") has recently officially disclosed its financial report for the fourth quarter and full year of 2025, while simultaneously updating the market on the latest business developments. - Bitget
TREVI THERAPEUTICS ($TRVI) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (TRVI) Trevi Therapeutics Posts Q4 Loss $-0.06, vs. FactSet Est of Loss of $-0.10 - marketscreener.com
TRVI: Advanced Haduvio in late-stage trials, but remains pre-revenue and reliant on future funding - TradingView
Trevi Therapeutics 10-K: Net loss $42.8M; loss from operations $49.3M - TradingView
Trevi Therapeutics announces March 17 earnings call for year end 2025 - Traders Union
TRVI: Positive Phase 2 results and FDA alignment set stage for pivotal Phase 3 trials in 2026 - TradingView
Trevi Therapeutics (TRVI) highlights strong Haduvio cough data and 2026 Phase 3 plans - Stock Titan
Trevi targets chronic cough with no FDA-approved drugs in Phase 3 push - Stock Titan
Assessing Trevi Therapeutics (TRVI) Valuation After FDA Alignment On Phase 3 IPF Chronic Cough Program - simplywall.st
A Look At Trevi Therapeutics (TRVI) Valuation After FDA Green Light For Phase 3 Trials - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Down 17.2% After Doubling Down On Parallel IPF Cough TrialsAnd What's Next - simplywall.st
Trevi Therapeutics, Inc. $TRVI Stock Position Increased by Pivotal bioVenture Partners Investment Advisor LLC - MarketBeat
Rosalind Advisors Inc. Trims Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics chief Farrell Simon to address pre launch excellence at U.S. rare disease event - Traders Union
Trevi Therapeutics at Leerink Global: Strategic Cough Treatment Advances By Investing.com - Investing.com Canada
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control (NASDAQ:TRVI) - Seeking Alpha
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion - The Globe and Mail
Zacks.com spotlighted features include Trevi, Metalla Royalty & Streaming, and Vermilion - Bitget
Q4 and year end 2025 earnings call announced, Trevi Therapeutics outlines - Traders Union
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 - WFMZ.com
Trevi Therapeutics to detail 2025 results and business updates Mar. 17 - Stock Titan
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on TRVI (March 09, 2026) - Meyka
Trevi Therapeutics (TRVI) Secures FDA Support for Advanced Clini - GuruFocus
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials - TipRanks
Trevi Therapeutics (NASDAQ: TRVI) advances nalbuphine ER into two Phase 3 IPF chronic cough trials - Stock Titan
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March - The Globe and Mail
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
TRVI: D. Boral Capital Maintains Buy Rating with $19 Target | TR - GuruFocus
Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 9.9%Here's What Happened - MarketBeat
Trevi Therapeutics (TRVI) Advances with Phase 3 Trials for Haduv - GuruFocus
HC Wainwright Reiterates Buy Rating for Trevi Therapeutics (TRVI) at $21 | TRVI Stock News - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):